Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Aytu Biopharma (AYTU) EPS (Basic) (2016 - 2025)

Aytu Biopharma has reported EPS (Basic) over the past 15 years, most recently at $3.98 for Q2 2025.

  • Quarterly EPS (Basic) rose 585.58% to $3.98 in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $3.99 through Dec 2025, up 427.09% year-over-year, with the annual reading at -$2.26 for FY2025, 20.98% up from the prior year.
  • EPS (Basic) was $3.98 for Q2 2025 at Aytu Biopharma, up from $0.01 in the prior quarter.
  • Over five years, EPS (Basic) peaked at $3.98 in Q2 2025 and troughed at -$35.9 in Q1 2022.
  • The 5-year median for EPS (Basic) is -$0.77 (2021), against an average of -$4.5.
  • Year-over-year, EPS (Basic) tumbled 6117.14% in 2021 and then skyrocketed 585.58% in 2025.
  • A 5-year view of EPS (Basic) shows it stood at -$8.74 in 2021, then soared by 75.4% to -$2.15 in 2022, then surged by 98.14% to -$0.04 in 2023, then soared by 150.41% to $0.02 in 2024, then surged by 19647.61% to $3.98 in 2025.
  • Per Business Quant, the three most recent readings for AYTU's EPS (Basic) are $3.98 (Q2 2025), $0.01 (Q1 2025), and $0.02 (Q4 2024).